Description: Fiximac-CV consist of third-generation cephalosporin antibiotic and a beta-lactamase inhibitor used to treat various bacterial infections caused by gram positive and negative bacetria. Pharmaceutical Dosage Form: Tablet Route of Administration: Oral Composition: Each film coated tablet contains: Cefixime IP as a trihydrate equivalent to Anhydrous Cefixime 200 mg Potassium Clavulanate Diluted, IP equivalent to Clavulanic Acid 125 mg Excipients q.s. Mechanism of Action: Cefixime exerts its antibacterial action by inhibiting the synthesis of bacterial cell walls through binding to penicillin-binding proteins, disrupting the formation of the cell wall and leading to bacterial cell death. Clavulanic acid contains a beta-lactam ring in its structure that binds in an irreversible way to beta-lactamases, preventing them from inactivating certain beta-lactam antibiotics, with efficacy in treating susceptible Gram-positive and Gram-negative infections. Indications: Fiximac-CV is indicated for the treatment of a wide range of bacterial infections targeting Upper respiratory tract, Lower respiratory tract and Urinary tract. Dosage: As prescribed by the physician. Storage: Protect from light and store below 300 Presentation: 10X1X10 Side effects: Nausea Abdominal pain Diarrhea Dyspepsia Flatulence Fall in prothrombin activity Transient elevations in SGPT, SGOT, alkaline phosphatase etc. Contraindications: Fiximac-CV is contraindicated in patients with a known allergy to Cefixime or to the Cephalosporin group of antibiotics. Drug Interactions: Fiximac-CV can interact with other drugs, potentially affecting their efficacy or increase the risk of side effects. Some notable drug interactions include – Warfarin & Anticoagulants Carbamazepine